Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

HAYWARD, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the third quarter ended September 30, 2010.

Financial Results

Total operating expenses for the third quarter ended September 30, 2010, were $8.4 million, as compared to $3.4 million for the same period in 2009. For the nine months ended September 30, 2010, total operating expenses were $22.8 million, as compared to $10.5 million for the same period in 2009. The increase in operating expenses during the quarter and year-to-date ended September 30, 2010 was primarily the result of increased site qualifications and clinical enrollment in the Company's Phase 3 clinical study VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) and clinical enrollment and manufacturing development activities for Anthera's A-623 Phase 2b study, known as PEARL-SC (A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A623 AdministRation in Subjects with Systemic Lupus Erythematosus). The quarterly and year-to-date results also reflect the expected increase in professional services and other costs associated with operating as a public company.

Anthera ended the third quarter of 2010 with approximately $73.1 million in cash and cash equivalents and short-term investments. Included in this amount is approximately $29.1 million in net proceeds pursuant to a private placement offering which closed on September 24, 2010. On November 1, 2010 the Department of Treasury notified Anthera that approximately $1.0M in grants have been approved under section 48D of the Internal Revenue Service code.

Recent Business Highlights

Regulatory

  • During the third quarter, enro
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
    2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
    3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
    4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
    (Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
    (Date:6/29/2015)... -- Allergan plc (NYSE: AGN ) today announced ... financial results on Thursday, August 6, 2015, prior ... Company will host a conference call and webcast ... August 6, 2015 to discuss its financial results. The ... Canada (877) 251-7980, International (706) ...
    Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 2Allergan to Host Second Quarter 2015 Earnings Conference Call and Webcast 3
    ... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced financial results for the quarter ... in this press release should be read in ...
    ... Southern Home Medical Equipment, Inc. (PINKSHEETS: SHOM), a ... equipment to medical institutions, announced today that Encore ... significant growth from Encore Medical Staffing operations in ... started this franchise in December, 2010," says Dr. ...
    Cached Medicine Technology:Dyadic International Reports 2011 First Quarter Financial Results 2Dyadic International Reports 2011 First Quarter Financial Results 3Dyadic International Reports 2011 First Quarter Financial Results 4Dyadic International Reports 2011 First Quarter Financial Results 5Southern Home Medical Equipment Reports Significant Growth from Encore Franchisees 2
    (Date:6/30/2015)... , ... June 30, 2015 ... ... the drug response profiling test to help oncologists provide personalized cancer treatment, ... “The CorrectChemo® assay provides the oncologist with valuable insight on how a ...
    (Date:6/30/2015)... ... June 30, 2015 , ... ... has joined Allegheny Health Network (AHN) as Director of its Adult ... management of primary brain tumors, brain metastases, leptomeningeal disease and the neurological complications ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Harbor Village Detox is a ... in Florida on June 12th. Holly Vasquez-Cortella was recently quoted as an expert ... dedicated to reporting on trending addiction news and treatment innovations. The article highlights Florida ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Under Armour’s ... at less thickness than any other padding in football. , Developed in partnership ... shock absorption, Gameday Armour is engineered with D3O protective polymer. This radical polymer ...
    (Date:6/30/2015)... ... June 30, 2015 , ... It has become fairly common to purchase fresh ... discard the stalks before cooking. Throwing out radish greens, beet leaves and chard stalks ... delicious. It just takes a little knowledge and practice to use them. Josie's ...
    Breaking Medicine News(10 mins):Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 2Health News:Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program 3Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 2Health News:Harbor Village Detox’s Clinical Director Is Quoted as an Addiction Expert by The Fix 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 4
    ... billion people suffer from preventable, treatable diseases around,the ... director Global Health Progress, TOYAKO, Japan, July ... World Health Organization (WHO) and,the Drugs for Neglected ... to,recognize the importance of neglected diseases as a ...
    ... July 8 Bristol-Myers Squibb, an,international pharmaceutical manufacturer, ... at multiple industrial facilities around,the country at a ... of,the Clean Air Act, U.S. Environmental Protection Agency ... an agreement filed in federal court in Evansville, ...
    ... which patients are most likely to respond to Herceptin , , ... determine whether a breast cancer patient is likely to respond ... by the U.S. Food and Drug Administration. , ... of the HER2 gene, which regulates the growth of cancer ...
    ... At 12:00 noon on July 8, 2008, J.,Douglas ... P.C.,filed the first drug product liability action in ... former Governor Engler,s grant of immunity,to drug manufacturers., ... was filed in the United,States District Court, Eastern ...
    ... of scientific evidence shows that cholesterol-reducing medications known as ... safety of these medications has been well documented, as ... prescription for statins take the drug for less than ... cost, adverse effects, poor understanding of statin benefits and ...
    ... to Serve Seniors and Disabled Through ... BEACH, Calif., July 8 Arthur Henkel, a ... been appointed vice,president of mergers and acquisitions for ... announced today. With this appointment, the,not-for- profit health ...
    Cached Medicine News:Health News:Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases 2Health News:Bristol-Myers Squibb Agrees to Clean Air Act Upgrades 2Health News:Bristol-Myers Squibb Agrees to Clean Air Act Upgrades 3Health News:FDA Approves Genetic Test for Breast Cancer 2Health News:National Class Action Filed Against Manufacturer of Digitek(R) (Prescription Drug) in Federal Court in Michigan 2Health News:Fish oil and red yeast rice studied for lowering blood cholesterol 2Health News:SCAN Health Plan Appoints Arthur Henkel Vice President of Mergers and Acquisitions 2
    ... factor I (IGF-I or somatomedin C) is a ... It acts as a potent mitogen of cellular ... cell-surface receptors. In the circulation, IGF-I is bound ... the actions of IGF-I by modulating the interaction ...
    ... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
    The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
    Image Diagnostics' Aspect100U is specifically designed for ease of use and high quality image outcome during urological procedures. Aspect tables benefit from a trim, lightweight design, ensuring a s...
    Medicine Products: